olodaterol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4814 868049-49-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olodaterol
  • olodaterol hydrochloride
  • BI 1744 CL
  • striverdi respimat
  • olodaterol HCl
  • BI 1744
  • BI-1744
a long-acting beta2-adrenergic agonist (LABA), activation of beta2 receptors in the airways results in a stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3',5' adenosine monophosphate (cAMP), elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells
  • Molecular weight: 386.45
  • Formula: C21H26N2O5
  • CLOGP: 1.44
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 4
  • TPSA: 100.05
  • ALOGS: -3.74
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mcg Inhal.solution

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 15.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.45 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 31, 2014 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyspnoea 62.29 44.79 24 135 78709 2279217
Chronic obstructive pulmonary disease 56.33 44.79 13 146 7064 2350862

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyspnoea 46.39 38.26 20 139 52039 1694583
Chronic obstructive pulmonary disease 42.16 38.26 11 148 5942 1740680

Pharmacologic Action:

SourceCodeDescription
ATC R03AC19 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03AL06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
CHEBI has role CHEBI:35522 beta-adrenergic agonist
CHEBI has role CHEBI:35523 bronchodilator agent
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
FDA EPC N0000175779 beta2-Adrenergic Agonist
FDA MoA N0000009922 Adrenergic beta2-Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic obstructive lung disease indication 13645005 DOID:3083

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.32 acidic
pKa2 11.96 acidic
pKa3 13.95 acidic
pKa4 8.47 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 6988496 Feb. 23, 2020 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 8044046 Nov. 10, 2023 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8044046 Nov. 10, 2023 TREATMENT OF COPD
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 7220742 May 12, 2025 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 8034809 May 12, 2025 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 7220742 May 12, 2025 TREATMENT OF RESPIRATORY COMPLAINTS
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8034809 May 12, 2025 TREATMENT OF COPD
EQ 0.0025MG BASE/INH STRIVERDI RESPIMAT BOEHRINGER INGELHEIM N203108 July 31, 2014 RX SPRAY, METERED INHALATION 7396341 Oct. 10, 2026 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION Oct. 5, 2021 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 9.14 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Beta-1 adrenergic receptor GPCR Ki 7.33 SCIENTIFIC LITERATURE
Beta-3 adrenergic receptor GPCR Ki 5.26 SCIENTIFIC LITERATURE

External reference:

IDSource
D10020 KEGG_DRUG
4033628 VUID
N0000190930 NUI
C2934193 UMLSCUI
65R445W3V9 UNII
869477-96-3 SECONDARY_CAS_RN
715600003 SNOMEDCT_US
015412 NDDF
1546059 RXNORM
d08261 MMSL
4033628 VANDF
704459002 SNOMEDCT_US
11504295 PUBCHEM_CID
CHEBI:82700 CHEBI
CHEMBL605846 ChEMBL_ID
9174 INN_ID
DB09080 DRUGBANK_ID
CHEMBL2105743 ChEMBL_ID
7543 IUPHAR_LIGAND_ID
C549647 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Stiolto Respimat HUMAN PRESCRIPTION DRUG LABEL 2 0597-0155 SPRAY, METERED 2.74 ug RESPIRATORY (INHALATION) NDA 19 sections
Striverdi Respimat HUMAN PRESCRIPTION DRUG LABEL 1 0597-0192 SPRAY, METERED 2.50 ug RESPIRATORY (INHALATION) NDA 20 sections